Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575984 | 0.86 | MTOR (0.69) | MTORMAPK14LSSHDAC3HDAC1 | |
| SCHEMBL184791 | 0.86 | MLYCD (0.51) | MTORMAPK14MEN1ALDH1A1GAA | |
| SCHEMBL16269079 | 0.84 | MTOR (0.51) | MTORMAPK14LSSHDAC3HDAC1 | |
| SCHEMBL26119278 | 0.84 | MLYCD (0.52) | MTORALDH1A1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL11533429 | 0.83 | CYP2C9 (0.65) | HDAC1HDAC6MEN1ALDH1A1GAA | |
| SCHEMBL21387743 | 0.83 | HDAC3 (0.59) | MTORMAPK14LSSHDAC3HDAC1 | |
| SCHEMBL2629356 | 0.83 | LSS (0.59) | MTORMAPK14LSSHDAC3HDAC1 | |
| SCHEMBL3897948 | 0.83 | CYP2C9 (0.59) | MTORMAPK14LSSHDAC3HDAC1 | |
| SCHEMBL2634030 | 0.82 | MAPK14 (0.76) | MAPK14LSSHDAC3HDAC1HDAC2 | |
| SCHEMBL19928752 | 0.82 | CYP1A2 (0.49) | MAPK14LSSHDAC1HDAC6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-4281073-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023153506-A1 | METHOD FOR GENERATING CARBON DIOXIDE | 学校法人神戸学院 | 2023-08-17 | — | — | WO | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023101256-A1 | 5-ALPHA-REDUCTASE INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 주식회사 팜어스바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| WO-2022159986-A1 | COMBINATION OF A 3-(IMIDAZOL-4-YL)-4-(AMINO)-BENZENESULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER | Ikena Oncology, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-114751920-A | Antitumor compounds | 法马马有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114736219-A | Antitumor compounds | 法马马有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-109715605-B | Process for preparing carotenoid monoesters | 巴斯夫欧洲公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | MTOR 2691/4885MAPK14 1347/4885LSS 3325/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | MTOR 693/4885MAPK14 1905/4885LSS 553/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | MTOR 693/4885MAPK14 1905/4885LSS 553/4885 |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | MTOR 184/4885MAPK14 1693/4885LSS 291/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | MTOR 185/4885MAPK14 1690/4885LSS 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.